Abstract
The CYP2D6 gene codes for human cytochrome P450 2D6 enzyme, which is responsible for the metabolism of many psychiatric drugs. In schizophrenic patients treated with neuroleptics, decreased or loss of function CYP2D6 alleles may contribute to the development of tardive dyskinesia (TD), a movement disorder that frequently occurs with chronic neuroleptic treatment. The goal of this study was to determine whether the occurrence of TD is associated with CYP2D6 genotype in a cohort of Korean schizophrenics by employing a CYP450 GeneChip® oligonucleotide microarray and PCR assays to screen for 19 CYP2D6 alleles. Our results revealed that males with at least one decreased or loss of function allele have a moderately greater chance of developing TD than males with only wild-type alleles. Female schizophrenics did not have a significantly greater chance of developing TD. Our results demonstrate the utility of CYP2D6 microarrays to assess genotype status in this Korean cohort.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Glazer WM, Morgenstern H, Doucette JT . Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications J Clin Psychiatry 1993 54: (4) 133–139
Casey DE . Tardive dyskinesia and atypical antipsychotic drugs Schizophr Res 1999 35: (Suppl) S61–S66
Wszola BA, Newell KM, Sprague RL . Risk factors for tardive dyskinesia in a large population of youths and adults Exp Clin Psychopharmacol 2001 9: (3) 285–296
Morgenstern H, Glazer WM . Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study Arch Gen Psychiatry 1993 50: (9) 723–733
Morgenstern H, Glazer WM, Gibowski LD, Holmberg S . Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatient population J Chronic Dis 1987 40: (4) 319–327
Otani K, Aoshima T . Pharmacogenetics of classical and new antipsychotic drugs Ther Drug Monit 2000 22: (1) 118–121
Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ et al . Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution Pharmacogenetics 1997 7: (3) 193–202
Meyer UA, Zanger UM . Molecular mechanisms of genetic polymorphisms of drug metabolism Annu Rev Pharmacol Toxicol 1997 37: 269–296
Wang SL, Huang JD, Lai MD, Liu BH, Lai ML . Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6 Clin Pharmacol Ther 1993 53: (4) 410–418
Johansson I, Yue QY, Dahl ML, Heim M, Sawe J, Bertilsson L et al . Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine Eur J Clin Pharmacol 1991 40: (6) 553–556
Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM et al . Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin Clin Pharmacol Ther 1992 51: (4) 388–397
Brockmoller J, Kirchheiner J, Meisel C, Roots I . Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment Pharmacogenomics 2000 1: (2) 125–151
Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K et al . Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia Schizophr Res 1998 32: (2) 101–106
Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM . Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients Psychopharmacology (Berl) 1997 131: (2) 174–179
Ellingrod VL, Schultz SK, Arndt S . Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score Psychiatr Genet 2000 10: (1) 9–11
Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR . Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype Br J Psychiatry 1997 170: 23–26
Arthur H, Dahl ML, Siwers B, Sjoqvist F . Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia J Clin Psychopharmacol 1995 15: (3) 211–216
Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjoqvist F et al . Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects Pharmacogenetics 1995 5: (3) 159–164
Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L . Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population Pharmacogenetics 1996 6: (5) 441–447
Potkin SG, Shen Y, Pardes H, Phelps BH, Zhou D, Shu L et al . Haloperidol concentrations elevated in Chinese patients Psychiatry Res 1984 12: (2) 167–172
Someya T, Suzuki Y, Shimoda K, Hirokane G, Morita S, Yokono A et al . The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population Psychiatry Clin Neurosci 1999 53: (5) 593–597
Roh HK, Chung JY, Oh DY, Park CS, Svensson JO, Dahl ML et al . Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients Br J Clin Pharmacol 2001 52: (3) 265–271
Suzuki Y, Someya T, Shimoda K, Hirokane G, Morita S, Yokono A et al . Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol Ther Drug Monit 2001 23: (4) 363–368
Llerena A, Dahl ML, Ekqvist B, Bertilsson L . Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers Ther Drug Monit 1992 14: (3) 261–264
Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T et al . Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics Schizophr Res 1998 32: (2) 107–113
Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M . Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation Mol Pharmacol 1994 46: (3) 452–459
Lam LC, Garcia-Barcelo MM, Ungvari GS, Tang WK, Lam VK, Kwong SL et al . Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients Pharmacopsychiatry 2001 34: (6) 238–241
Rey MJ, Schulz P, Costa C, Dick P, Tissot R . Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics Int Clin Psychopharmacol 1989 4: (2) 95–104
Guy W . Assessment Manual for Psychopharmacology Publication ADM, U.S. Department of Health, Education and Welfare 1976
Schooler NR, Kane JM . Research diagnoses for tardive dyskinesia Arch Gen Psychiatry 1982 39: (4) 486–487
Wang SL, Lai MD, Huang JD . G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese Drug Metab Dispos 1999 27: (3) 385–388
Yokoi T, Kosaka Y, Chida M, Chiba K, Nakamura H, Ishizaki T et al . A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype Pharmacogenetics 1996 6: (5) 395–401
Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR et al . Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology Pharmacogenetics 1995 5: (4) 215–223
Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM . Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6 Pharmacogenetics 2000 10: (7) 577–581
Claassen JD, Pascoe N, Schatzberg AF, Murphy Jr GM . Rapid detection of the C-1496G polymorphism in the CYP2D6*2 allele Clin Chem 2001 47: (12) 2153–2155
Murphy Jr GM, Pollock BG, Kirshner MA, Pascoe N, Cheuk W, Mulsant BH et al . CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression Neuropsychopharmacology 2001 25: (5) 737–743
Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS . Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data Pharmacogenetics 1999 9: (6) 669–682
Acknowledgements
We gratefully acknowledge Tom Ryder for advice in designing the new CYP450 GeneChip® microarray. This study was supported in part by a grant-in-aid from Research Foundation of Inje University (1999).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nikoloff, D., Shim, JC., Fairchild, M. et al. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J 2, 400–407 (2002). https://doi.org/10.1038/sj.tpj.6500138
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500138
Keywords
This article is cited by
-
Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study
BMC Medical Genetics (2013)
-
Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses
The Pharmacogenomics Journal (2011)
-
Applications of AmpliChip™ CYP450
Molecular Diagnosis (2005)
-
Clinical implications of pharmacogenomics for tardive dyskinesia
The Pharmacogenomics Journal (2004)